How to use Ruxolitinib cream-Opzelura

Ruxolitinib cream (Ruxolitinib cream)-Opzelura is mainly used to treat atopic dermatitis (AD) and non-segmental vitiligo. Its use must strictly follow the doctor's instructions to ensure safety and effectiveness.

When using ruxolitinib ointment, you should first ensure that the skin is clean and dry. To use, apply a thin layer of ointment to the affected area at a time. For patients with atopic dermatitis, it is recommended to apply the ointment twice daily to no more than 20% of the affected areas of the body surface area. Use should be stopped promptly when symptoms such as itching, rash, and redness subside. If symptoms do not improve within 8 weeks, patients should consult their physician for further evaluation and adjustment of treatment plan.

For patients with non-segmental vitiligo, it is also recommended to apply twice a day, but the scope of application is limited to 10% of the body surface area. In some cases, achieving satisfactory efficacy may require a longer period of continuous use, usually more than 24 weeks. If there are no significant pigmentation changes during this time, the patient should be re-evaluated by a physician to decide whether to continue treatment or adjust the regimen.

During the medication process, patients should be careful not to apply ruxolitinib ointment to the eyes, mouth, or other mucosal areas. At the same time, to avoid potential interactions, it is not recommended to use it in combination with other therapeutic biologics, other JAK inhibitors or powerful immunosuppressants. In addition, there are strict limits on weekly usage, with patients not allowed to exceed one 60-gram test tube per week, and no more than one 100-gram test tube every two weeks. This is to prevent overdose and reduce the risk of side effects.

During the period of medication, patients should regularly monitor their skin status and inform their doctor in time if any abnormal reactions or discomfort occur. The doctor will make corresponding treatment adjustments based on the patient's specific situation. This close follow-up and communication can effectively ensure patient safety and improve treatment effectiveness.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=24da5509-6631-4795-9d42-273faecd08e7